Skip to content

Clinical study on the intervention of clinical pharmacists with Budesonide /Glycopyrronium /Formoterol in COPD patients

Clinical study on the intervention of clinical pharmacists with Budesonide /Glycopyrronium /Formoterol in COPD patients

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090585
Enrollment
Unknown
Registered
2024-10-09
Start date
2023-10-11
Completion date
Unknown
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Control group: routine diagnosis and treatment
observation group: On the basis of routine diagnosis and treatment, clinical pharmacist intervention was added to the experimental group, including medication guidance, psychological counseling, healt

Sponsors

The First Hospital of Putian City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of the Guidelines for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (Revised 2021), and be diagnosed with COPD; (2) The use of Budigalf; (3) Age 40-80 years old; (4) Clear awareness, barrier-free communication and the ability to correctly express their wishes

Exclusion criteria

Exclusion criteria: (1) Allergic to the drug in this study; (2) failure to cooperate with follow-up plans; (3) suffering from mental disorders, serious organic diseases, liver and kidney dysfunction; (4) Non-COPD patients.

Design outcomes

Primary

MeasureTime frame
Inhalant score ; CAT score; mMRC rating;compliance;anxiety (SAS) and depression (SDS) scales;

Secondary

MeasureTime frame
body mass index;

Countries

China

Contacts

Public ContactMeiying Lin

The First Hospital of Putian City

linmeiyingfujian@163.com+86 187 5005 5386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026